Alvotech logo — Better Access. Better Lives.

Alvotech

Better Access. Better Lives.

Founded 2013 Iceland Iceland 884 employees Corporate Total: $1.82B Biotechnology, Life Sciences +1

General Information

Company Name Alvotech
Founded Year 2013
Location Iceland Iceland
Employees 884
Industries Biotechnology, Life Sciences, Pharmaceutical
Funding Stage Corporate
Social

BounceWatch is an independent company data service, not affiliated with Alvotech. To contact Alvotech, visit alvotech.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Alvotech compare?

A PDF of Alvotech and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Alvotech soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Alvotech

Alvotech is a biotechnology and pharmaceutical company based in Iceland, with a mission to improve patient lives and the sustainability of the global healthcare ecosystem. Since its establishment in 2013, the company has been committed to broadening the availability and accessibility of biosimilars to ultimately achieve "Better Access. Better Lives." Notably, the company secured a significant $900.00M post-IPO debt investment on June 7, 2024, demonstrating a strong financial backing and potential for growth. This investment milestone signifies the confidence of investors in Alvotech's innovative approach and its potential to make a substantial impact in the biopharmaceutical industry.

Business keywords: biosimilars, patient, accessibility, global health

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Corporate €100.00M 1
GoldenTree Asset Management
02 Jan 2026
Post IPO Debt $965.00M -
07 Jun 2024
Post IPO Debt $100.00M -
31 Jul 2023
Post IPO Equity $137.00M -
23 Jan 2023
Post IPO Debt $70.00M -
16 Dec 2022
Venture Round $35.00M -
15 Mar 2021
Venture Round $65.00M 5
Athos Capital, Baxter Ventures +3
27 Oct 2020
Debt Financing $300.00M -
22 Jan 2019
Corporate Round $50.00M 1
Fuji Pharma
17 Dec 2018

Alvotech Alternatives & Competitors

View All Alternatives
Alvotech vs

Boosting access to therapeutic advances through entrepreneurial agility

21 employees
Biotechnology, Health Care
Alvotech vs

Recreating a future for Parkinson's

Post-IPO Equity
171 employees
Biotechnology, Health Care
Alvotech vs
Takeda
Takeda Japan

Better Health, Brighter Future

IPO
37130 employees
Biotechnology, Pharmaceutical

FAQ About Alvotech

Better Access. Better Lives.
Alvotech was founded in 2013.
Alvotech is headquartered in Iceland.
Alvotech operates in Biotechnology, Life Sciences and Pharmaceutical. Its work centres on biosimilars, patient, accessibility and global health.
Alvotech has approximately 884 employees.
Alvotech has completed 9 funding rounds, raising a total of $1.82B. The latest funding stage is Corporate.
Top alternatives and competitors to Alvotech include iQone Healthcare Switzerland, NeuroDerm, A Mitsubishi Tanabe Pharma Group Company, Takeda, Celltrion Inc, Elanco. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Alvotech and iQone Healthcare Switzerland are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Alvotech, https://bouncewatch.com/company/alvotech, updated 2 January 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes